Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
The company ditches lorigerlimab in prostate cancer.
The response rate jumps to 30% with higher doses of IMA402.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
The CD70-targeting CTX131 heads for the scrapheap.
After more discontinuations, a new deal brings in fresh blood.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
